According to a market report by Lucintel, the future of the global non-invasive cancer diagnostic market looks promising with opportunities in the solid tumors, blood cancer, lung cancer, and breast cancer markets. The global non-invasive cancer diagnostic market is expected to reach an estimated $199.2 billion by 2030 with a CAGR of 6.8% from 2024 to 2030. The major drivers for this market are the rising concerns of chronic cancer, introduction of advanced bio marker based detection methods,and supportive government initiative to promote the use of non-invasive diagnostic test.
A more than 150-page report to understand trends, opportunity and forecast in non-invasive cancer diagnostic market to 2030 by therapeutics (solid tumors, blood cancer, lung cancer,breast cancer, and others), technology (clinical chemistry, immunochemistry, molecular diagnostics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel forecast that clinical chemistry is expected to witness highest growth over the forecast period due to its various advantages, including highly sensitive, low cost, and widespread availibility.
Breast cancer will remain the largest segment due to increasing number of breast cancer patients around the world.
Download sample by clicking on non-invasive cancer diagnostic market
North America is expected to witness highest growth over the forecast period due to existence of well-established health infrastructure, growing prevalence of cancer related cases among people, and presence of key players in the region.
Precision Therapeutics, A&G Pharmaceutical, Affymetrix, AVIVA Biosciences, BIOVIEW, Laboratory Corporation Of America, Quest Diagnostics Incorporated Cancer Genetics, Digene, Gen-Probe, IVDiagnostics are the major suppliers in the non-invasive cancer diagnostic market.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at [email protected] To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.
About Lucintel
At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: [email protected]
Tel. +1-972-636-5056
Explore Our Latest Publications
Aflatoxin Rapid Test Kit Market
Alanine Market
Anti-streptolysin O Assay Kit Market
Brain Function Ultrasound Imaging System Market
Carbinoxamine Maleate Market